Sensex 29278.84 272.82 0.94%
Nifty 8835.6 74.2 0.85%
Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has launched its Fenofibrate Tablets, 48 mg and 145 mg strengths in the United States. Lupin had earlier received final approval for the same from the US Food and Drug Administration (FDA).
Lupin's Fenofibrate tablets are the AB rated generic equivalent of Abbott's TRICOR* tablets and are indicated for Primary Hypercholesterolemia or Mixed Dyslipidemia and Severe Hypertriglyceridemia. Abbott's TRICOR* Tablets, 48 mg and 145 mg had sales of U5D 1.26 billion as per IMS Health, June, 2012,
Commenting on the approval, Vinita Gupta, CEO, Lupin Pharmaceuticals Inc. & Group President, Lupin Limited said, "We are very happy to bring this product to market in the United States. Patients can be assured that they are receiving the same high quality product they have been accustomed to at a more affordable price".
India Infoline News Service / 09:04, Jan 22, 2015
The outlook is a flat start. The market will look to scale to new peaks though not much effort is needed for the same. HUL saw a rally and short-covering may have pulled it up further. Speculation is on that its parent will raise stake through an open offer. After the cooling in oil prices, Cairn results will be in focus.